Ингибирование теломеразы человека (1105569), страница 18
Текст из файла (страница 18)
P. 1115-1123.Harrison R.J., Gowan S.M., Kelland L.R., Neidle S. Human telomeraseinhibition by substituted acridine derivatives. // Bioorg Med Chem Lett. 1999.V. 9. P. 2463-2468.Read M., Harrison R.J., Romagnoli B., Tanious F.A., Gowan S.H., ReszkaA.P., Wilson W.D., Kelland L.R., Neidle S. Structure-based design ofselective and potent G quadruplex-mediated telomerase inhibitors. // ProcNatl Acad Sci U S A. 2001.
V. 98. P. 4844-4849.Gowan S.M., Harrison J.R., Patterson L., Valenti M., Read M.A., Neidle S.,Kelland L.R. A G-quadruplex-interactive potent small-molecule inhibitor oftelomerase exhibiting in vitro and in vivo antitumor activity. // MolPharmacol. 2002. V. 61. P. 1154-1162.Nandakumar J., Cech T.R. Finding the end: recruitment of telomerase totelomeres. // Nat Rev Mol Cell Biol. 2013. V.
14. P. 69-82.Salvati E., Leonetti C., Rizzo A., Scarsella M., Mottolese M., Galati R., et al.Telomere damage induced by the G-quadruplex ligand RHPS4 has anantitumor effect. // J. Clin. Investig. 2007. V. 117. P. 3236–3247.Gomez D., Aouali N., Renaud A., Douarre C., Shin-Ya K., Tazi J., et al.Resistance to senescence induction and telomere shortening by a Gquadruplex ligand inhibitor of telomerase. // Cancer Res. 2003. V.
63. P.6149–6153.Martins C., Gunaratnam M., Stuart J., Makwana V., Greciano O., ReszkaA.P., Kelland L.R., Neidle S. Structure-based design of benzylamino-acridinecompounds as G-quadruplex DNA telomere targeting agents. // Bioorg MedChem Lett. 2007. V. 17.
P. 2293–2298.127[105] Url: http://clinicaltrials.gov/show/NCT00955786[106] Drygin D., Siddiqui-Jain A., O’Brien S., Schwaebe M., Lin A., Bliesath J., etal. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. //Cancer Res. 2009. V. 71. P. 1418–1430.[107] Sadlak R.H., Jerome K.R. Viral diagnostics in the era of digital polymerasechain reaction. // Diagn Microbial Infect Dis.
2013. V. 75. P. 1-4.[108] Zhou Y., Zhu S., Cai C., Yuan P., Li C., Huang Y., Wei W. High-throughputscreening of a CRISPR/Cas9 library for functional genomics in human cells.// Nature. 2014. V. 509. P. 487-491.[109] Martínez T., Wright N., López-Fraga M., Jiménez A.I., Pañeda C. Silencinghuman genetic diseases with oligonucleotide-based therapies. // Hum Genet.2013. V. 132. P. 481-493.[110] Dassie J.P., Giangrande P.H. Current progress on aptamer-targetedoligonucleotide therapeutics. // Ther Deliv. 2013.
V. 4. P. 1527-1546.[111] Burnett J.C., Rossi J.J. RNA-based therapeutics: current progress and futureprospects. // Chem Biol. 2012. V. 19. P. 60-71.[112] Merdan T., Kopecek J., Kissel T. Prospects for cationic polymers in gene andoligonucleotide therapy against cancer. // Adv Drug Deliv Rev. 2002. V. 54. P.715-758.[113] Vivek K.S., Raman K.S., Sunil K.S. Antisense oligonucleotides:modifications and clinical trials. // Med. Chem. Commun. 2014.
V. 5. P. 14541471.[114] Dirin M., Winkler J. Influence of diverse chemical modifications on theADME characteristics and toxicology of antisense oligonucleotides. // ExpertOpin Biol Ther. 2013. V. 13. P. 875-888.[115] Juliano R.L., Carver K., Cao C., Ming X. Receptors, endocytosis, andtrafficking: the biological basis of targeted delivery of antisense and siRNAoligonucleotides. // J Drug Target.
2013. V. 21. P. 27-43.[116] Corey D.R. Telomerase inhibition, oligonucleotides, and clinical trials. //Oncogene. 2002. V. 21. P. 631-637.[117] Prakash T.P., Bhat B. 2'-Modified oligonucleotides for antisense therapeutics.// Curr Top Med Chem. 2007. V. 7. P. 641-649.[118] Elayadi A.N., Demieville A., Wancewicz E.V., Monia B.P., Corey D.R.Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect oflength, phosphorothioate substitution and time inside cells. // Nucleic AcidsRes.
2001. V. 29. P. 1683-1689.[119] Eckstein F. Phosphorothioate oligodeoxynucleotides: what is their origin andwhat is unique about them? // Antisense Nucleic Acid Drug Dev. 2000. V. 10.128[120][121][122][123][124][125][126][127][128][129][130]P. 117-121.Saeki T., Takashima S., Tachibana M., Koga M., Hiyama E., Salomon D.S.,Holland J.F., Ohnuma T. Inhibitory effect of telomere-mimicphosphorothioate oligodeoxy nucleotides (S-ODNS) on human tumor celllines.
// Oncology. 1999. V. 57. P. 27-36.Pongracz K., Li S., Herbert B.S., Pruzan R., Wunder E., Chin A., PiatyszekM., Shay J., Gryaznov S.M. Novel short oligonucleotide conjugates asinhibitors of human telomerase. // Nucleosides Nucleotides Nucleic Acids.2003. V. 22. P. 1627-1629.Henry S.P., Novotny W., Leeds J., Auletta C., Kornbrust D.J.
Inhibition ofcoagulation by a phosphorothioate oligonucleotide. // Antisense Nucleic AcidDrug Dev. 1997. V. 7. P. 503-510.Gryaznov S., Asai A., Oshima Y., Yamamoto Y., Pongracz K., Pruzan R.,Wunder E., Piatyszek M., Li S., Chin A., Harley C., Akinaga S., YamashitaY. Oligonucleotide N3' --> P5' thio-phosphoramidate telomerase templateantagonists as potential anticancer agents.
// Nucleosides Nucleotides NucleicAcids. 2003. V. 23. P. 577-581.С.И.А.Пептидно-нуклеиновые кислоты:структура,свойства,применение, стратегии и практика химического синтеза. –M.: Успехихимии, 2002.Tarkanyi I., Aradi J. Pharmacological intervention strategies for affectingtelomerase activity: future prospects to treat cancer and degenerative disease.// Biochimie. 2008. V.
90. P. 156-172.Hamilton S.E., Simmons C.G., Kathiriya I.S., Corey D.R. Cellular delivery ofpeptide nucleic acids and inhibition of human telomerase. // Chem Biol. 1999.V. 6. V. 343-351.Ishihara T., Kano A., Obara K., Saito M., Chen X., Park T.G., Akaike T.,Maruyama A. Nuclear localization and antisense effect of PNA internalizedby ASGP-R-mediated endocytosis with protein/DNA conjugates. // J ControlRelease. 2011. V. 155.
P. 34-39.Du Q.Y., Wang X.B., Chen X.J., Zheng W., Wang S.Q. Antitumormechanism of antisense cantide targeting human telomerase reversetranscriptase. // World J Gastroenterol. 2003. V. 9. P. 2030-2035.Yang Y., Lv Q.J., Du Q.Y., Yang B.H., Lin R.X., Wang S.Q. Combinedeffects of Cantide and chemotherapeutic drugs on inhibition of tumor cells'growth in vitro and in vivo.
// World J Gastroenterol. 2005. V. 11. P. 24912496.Lin R.X., Tuo C.W., Lü Q.J., Zhang W., Wang S.Q. Inhibition of tumor129[131][132][133][134][135][136][137][138][139][140][141]growth and metastasis with antisense oligonucleotides (Cantide) targetinghTERT in an in situ human hepatocellular carcinoma model. // ActaPharmacol Sin. 2005. V. 26. P. 762-768.Skvortzov D.A., Rubzova M.P., Zvereva M.E., Kiselev F.L., Donzova O.A.,The regulation of telomerase in oncogenesis. // Acta Naturae. 2009. V.
1. P.51-67.Petrenko A.A., Korolenkova L.I., Skvortsov D.A., Fedorova M.D., SkoblovM.U., Baranova A.V., Zvereva M.E., Rubtsova M.P., Kisseljov F.L. Cervicalintraepithelial neoplasia: Telomerase activity and splice pattern of hTERTmRNA. // Biochimie. 2010. V. 92. P. 1827-1831.Wong M.S., Chen L., Foster C., Kainthla R., Shay J.W., Wright W.E.Regulation of telomerase alternative splicing: a target for chemotherapy. //Cell Rep. 2013. V.
3. P. 1028-1035.Bernardes de Jesus B., Blasco M.A. Telomerase at the intersection of cancerand aging. // Trends Genet. 2013. V. 29. P. 513-520.Mukai S., Kondo Y., Koga S., Komata T., Barna B.P., Kondo S. 2-5Aantisense telomerase RNA therapy for intracranial malignant gliomas. //Cancer Res. 2000. V. 60. P. 4461-4467.Keppler B.R., Jarstfer M.B.
Inhibition of telomerase activity by preventingproper assemblage. // Biochemistry. 2004. V. 43. P. 334-343.Vasilkova D.V., Azhibek D.M., Zatsepin T.S., Naraikina Y.V., PrassolovV.S., Prokofjeva M.M., Zvereva M.I., Rubtsova M.P. Dynamics of humantelomerase RNA structure revealed by antisense oligonucleotide technique.
//Biochimie. 2013. V. 95. P. 2423-2428.Kondo Y., Kondo S. Telomerase RNA inhibition using antisenseoligonucleotide against human telomerase RNA linked to a 2',5'oligoadenylate. // Methods Mol Biol. 2007. P. 405. P. 97-112.Gude L., Berkovitch S.S., Santos W.L., Kutchukian P.S., Pawloski A.R.,Kuimelis R., McGall G., Verdine G.L.
Mapping targetable sites on humantelomerase RNA pseudoknot/template domain using 2'-OMe RNA-interactingpolynucleotide (RIPtide) microarrays. // J Biol Chem. 2012. V. 287. P. 1884318853.Rubtsova M.P., Vasilkova D.P., Malyavko A.N., Naraikina Y.V., ZverevaM.I., Dontsova O.A. Telomere lengthening and other functions of telomerase.// Acta Naturae. 2012. V. 4. P. 44-61.Hay M., Thomas D.W., Craighead J.L., Economides C., Rosenthal J. Clinicaldevelopment success rates for investigational drugs.
// Nature Biotechnology.2014. V. 32. P. 40-51.130[142] Counter C.M., Avilion A.A., LeFeuvre C.E., Stewart N.G., Greider C.W.,Harley C.B., Bacchetti S. Telomere shortening associated with chromosomeinstability is arrested in immortal cells which express telomerase activity. //EMBO J. 1992. V.
11. P. 1921-1929.[143] Pruzan R., Pongracz K., Gietzen K., Wallweber G., Gryaznov S. Allostericinhibitors of telomerase: oligonucleotide N3'-->P5' phosphoramidates. //Nucleic Acids Res. 2002. V. 30. P. 559-568.[144] Behlke M., Devor E.J., Goodchild J. Designing Antisense Oligonucleotides. //Integrated DNA Technologies. 2005. P.
1-17.[145] Kurth I., Cristofari G., Lingner K. An Affinity Oligonucleotide DisplacementStrategy to Purify Ribonucleoprotein Complexes Applied to HumanTelomerase. // Methods Mol Biol. 2008. V. 488. P. 9-22.[146] Url:http://www.wolframalpha.com/widgets/view.jsp?id=b3caae6857cf5662d007d49b4ace0e05.[147] Cohen S.B., Reddel R.R. A sensitive direct human telomerase activity assay.// Nat Methods. 2008. V. 5.
P. 355-360.[148] Redon S., Reichenbach P., Lingner J. The non-coding RNA TERRA is anatural ligand and direct inhibitor of human telomerase. // Nucleic AcidsResearch. 2010. V. 38. P. 1-10.[149] Беспамятное Г. П. и др. Предельно-допустимые концентрации вредныхвеществ в воздухе и воде. – М.: Химия, 1975. 455 с.[150] Uehara H. Real-time detection and quantification of telomerase activityutilizing energy transfer primers. // Methods Mol Biol.
2006. V. 335. P. 157169.[151] Shchekotikhin A.E., Glazunova V.A., Dezhenkova L.G., Luzikov Y.N.,Sinkevich Y.B., Kovalenko L.V., Buyanov V.N., Balzarini J., Huang F.C.,Lin J.J., Huang H.S., Shtil A.A., Preobrazhenskaya M.N. Synthesis andcytotoxic properties of 4,11-bis[(aminoethyl)amino]anthra[2,3-b]thiophene5,10-diones, novel analogues of antitumor anthracene-9,10-diones. // BioorgMed Chem. 2009.
V. 17. P. 1861-1869.[152] Ilyinsky N.S., Shchyolkina A.K., Borisova O.F., Mamaeva O.K., ZverevaM.I., Azhibek D.M., Livshits M.A., Mitkevich V.A., Balzarini J., SinkevichY.B., Luzikov Y.N., Dezhenkova L.G., Kolotova E.S., Shtil A.A.,Shchekotikhin A.E., Kaluzhny D.N. Novel multi-targeting anthra[2,3b]thiophene-5,10-diones with guanidine-containing side chains: Interactionwith telomeric G-quadruplex, inhibition of telomerase and topoisomerase Iand cytotoxic properties. // Eur J Med Chem. 2014. V. 85.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
